Report cover image

Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 70 Pages
SKU # DEL18679328

Description

Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024



DelveInsight’s, ''Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Carbapenem-Resistant Enterobacteriaceae pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Carbapenem-Resistant Enterobacteriaceae Understanding

Antibiotic resistance is a growing problem. Resistance genes exist for all known antibiotics in use today, and extremely resistant pathogens are becoming more common. Gram-negative bacteria have developed the broadest spectrum of resistance due to multiple structural adaptations and antibiotic degradation enzymes, including expanded spectrum beta-lactamases (ESBL), AmpC cephalosporinases, and carbapenemases. Carbapenemase-producing Enterobacteriaceae (CRE) are of particular concern.

""Carbapenem-Resistant Enterobacteriaceae - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Carbapenem-Resistant Enterobacteriaceae pipeline landscape is provided which includes the disease overview and Carbapenem-Resistant Enterobacteriaceae treatment guidelines. The assessment part of the report embraces, in depth Carbapenem-Resistant Enterobacteriaceae commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Carbapenem-Resistant Enterobacteriaceae collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence R&D Carbapenem-Resistant Enterobacteriaceae. The therapies under development are focused on novel approaches to treat/improve Carbapenem-Resistant Enterobacteriaceae.
Carbapenem-Resistant Enterobacteriaceae Emerging Drugs

Durlobactam: Entasis Therapeutics

Durlobactam (DUR; previously designated ETX2514) is our novel, broad-spectrum and potent inhibitor of Class A, C, and D β-lactamases. Sulbactam (SUL) is a β-lactam antibiotic with activity against Acinetobacter baumannii; however, β-lactamase-mediated resistance to sulbactam is now widespread rendering it generally ineffective. In preclinical studies, durlobactam inhibits the β-lactamases commonly found in A. baumannii thus restoring sulbactam’s activity. We are developing SUL-DUR (previously designated ETX2514SUL), a combination of β-lactam antibiotic and a β-lactamase inhibitor for the treatment of serious infections cuased by Acinetobacter, including multidrug-resistant (MDR) strains.

Further product details are provided in the report……..

Carbapenem-Resistant Enterobacteriaceae: Therapeutic Assessment

This segment of the report provides insights about the Carbapenem-Resistant Enterobacteriaceae drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Carbapenem-Resistant Enterobacteriaceae
There are approx. 10+ key companies which are developing the therapies Carbapenem-Resistant Enterobacteriaceae. The companies which have their Carbapenem-Resistant Enterobacteriaceae drug candidates in the most advanced stage, i.e Phase III include Entasis Therapeutics
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Carbapenem-Resistant Enterobacteriaceae pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Intravenous
  • Subcutaneous
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Carbapenem-Resistant Enterobacteriaceae: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Carbapenem-Resistant Enterobacteriaceae therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Carbapenem-Resistant Enterobacteriaceae drugs.

Carbapenem-Resistant Enterobacteriaceae Report Insights
  • Carbapenem-Resistant Enterobacteriaceae Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Carbapenem-Resistant Enterobacteriaceae Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Carbapenem-Resistant Enterobacteriaceae drugs?
  • How many Carbapenem-Resistant Enterobacteriaceae drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Carbapenem-Resistant Enterobacteriaceae?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Carbapenem-Resistant Enterobacteriaceae therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Carbapenem-Resistant Enterobacteriaceae and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Vedanta Biosciences
  • Summit Therapeutics
  • SuperTrans Medical
  • Entasis Therapeutics
  • AGILeBiotics
  • Buywork
  • Nosopharm
Key Products
  • VE707
  • SMT-738
  • STM-004
  • Durlobactam
  • ABX-605
  • GYROX-2
  • NOSO-502

Table of Contents

70 Pages
Introduction
Executive Summary
Carbapenem-Resistant Enterobacteriaceae: Overview
What is Carbapenem-Resistant Enterobacteriaceae?
Types of Carbapenem-Resistant Enterobacteriaceae
Causes
Epidemiology and Risk Factors
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Carbapenem-Resistant Enterobacteriaceae– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Durlobactam: Entasis Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
NOSO-502: Nosopharm
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Carbapenem-Resistant Enterobacteriaceae Key Companies
Carbapenem-Resistant Enterobacteriaceae Key Products
Carbapenem-Resistant Enterobacteriaceae- Unmet Needs
Carbapenem-Resistant Enterobacteriaceae- Market Drivers and Barriers
Carbapenem-Resistant Enterobacteriaceae- Future Perspectives and Conclusion
Carbapenem-Resistant Enterobacteriaceae Analyst Views
Carbapenem-Resistant Enterobacteriaceae Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us